Low anterior resection syndrome (LARS)

LARS expert, Katrine Emmertsen, describes a mixed pathophysiological model for LARS in her article submitted for Faecal Incontinence Month.

Functional problems after sphincter preserving treatment of rectal cancer have been known since the 80s. As a result of the TME trials in Sweden (31) and the Netherlands (32) comparing surgery alone with neoadjuvant radiotherapy and surgery identified the magnitude of the functional problems has been recognised. The addition of neoadjuvant radiotherapy significantly increased these risks. LARS is more pronounced in females and in younger patients (33). This cannot be explained by pathophysiological findings alone but may be related to different coping strategies, age and the acceptance of chronic functional problems. A large Danish cohort (34) described the pattern cluster of symptoms now termed Low Anterior Resection Syndrome (LARS) consisting of faecal incontinence, flatulence, frequency of bowel movements, fragmented defecation, and faecal urgency with a significant negative impact on quality of life (Table 2). 

A mixed pathophysiological model for LARS:

Reservoir function of the neorectum

Standard rectal cancer treatment today is by total mesorectal excision with sphincter preservation if possible. Some patients require neoadjuvant therapy to downstage a potentially non-resectable cancer or to minimize the risk of local recurrence in resectable cancers. The surgical resection is thought to be the primary cause of LARS due to loss of reservoir function. Several efforts to restore reservoir function have been made in the form of coloplasty, side-to-end anastomosis and J-pouch. The main benefit of these modifications are in the first 1-2 years, but seems to diminish thereafter (35). Some studies have also shown that oncologically safe Partial Mesorectal Excision (PME) performs better from a functional standpoint than a Total Mesorectal Excision (TME) (36, 37) (Figure 1). Anal sphincter manometry has failed to show any significant change in anal sphincter function related to surgical or oncological treatment. Poor preoperative anal sphincter function is a strong predictor of LARS and should be taken into consideration at initial treatment planning.

Afferent sensory loss

The length of the rectal remnant retained as measured on MR scan correlates with a significantly better functional outcome (38). This beneficial effect is lost in irradiated patients. Both RCT’s and epidemiological studies show a greatly increased risk of severe LARS using neoadjuvant therapy (33, 36, 39, 40). This suggests that rectal function is highly dependent on afferent sensory input from the remaining mucosa distal to the anastomosis or from the pelvic sidewalls. Therefore, it is of importance to select patient who will actually benefit from radiotherapy.

The negative impact of a diverting stoma

A temporary stoma after TME is widely practiced in order to avoid the consequences of an anastomotic leak. A recent revisit of a randomised study comparing TME surgery with or without a diverting stoma showed that patients with a diverting stoma had an increased risk of developing LARS five years after surgery (41). The precise aetiology is not known, but could be related to diversion colitis, or to changes in epithelial function of the terminal ileum, causing bile acid malabsorption, small bowel bacterial overgrowth or bacterial re-colonisation of the colon after the stoma reversal.

Autonomic denervation

Food intake strongly stimulates faecal urgency in LARS patients and there is an increased gastrocolic reflex (42). This is probably caused by autonomic denervation of the neorectum although the bowel has its own neural network able to work independently of extrinsic sympathetic or parasympathetic innervation. Integrated autonomic function relies on extrinsic innervation. In general, the sympathetic nerves inhibit peristalsis, whereas the parasympathetic nerves promote peristalsis. After rectal resection the bowel proximal to the anastomosis is without parasympathetic and to some extent without sympathetic extrinsic innervation due to central vessel ligation causing damage to the sympathectic supply from the superior hypogastric plexus in the front of the aorta.

Chemotherapy and pelvic radiation disease

Chemotherapy-induced GI symptoms is related to small bowel bacterial overgrowth, bile acid malabsorption or pancreatic insufficiency, causing diarrhoea, flatulence, bloating, pain or constipation (43). Although modern radiotherapy aims to diminish the area receiving radiation, scatter still occurs to adjacent structures, such as to the small bowel, or to pelvic organs. In the longer term, radiation causes ischaemic and fibrotic changes as well as initial mucosal inflammation. Cell death results in impairment of GI physiological function. Chronic GI symptoms are caused by a variety of processes so that symptoms alone are unreliable at predicting the underlying cause (44). Further evaluation should include: vitamin B12, thyroid function , coeliac screen, Selenium homocholic acid taurine (Se HCAT) scan, glucose hydrogen breath test and both upper and lower GI endoscopy. Algorithm based management programs has proven effective in managing post resection symptoms which can be used by nurse specialists (45).

Unknown functional outcome following new treatment modalities for rectal cancer

Some small early cancers can be curatively treated by local excision alone. New options for curative chemoradiotherapy using a watch and wait policy or local excision after complete or partial response may avoid resectional therapy. The main argument for these new developments is a better functional outcome without oncological compromise. However the functional outcome of these procedures remains to be evaluated.

References

  1. Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2015;58(8):713-25. doi: 10.1097/DCR.0000000000000410.
  2. Excellence NIfHaC. Colorectal cancer: diagnosis and management 2011 7 February 2016. Available from: https://www.nice.org.uk/guidance/cg131.
  3. Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002;359(9314):1291-300.
  4. van de Wal M, van de Poll-Franse L, Prins J, Gielissen M. Does fear of cancer recurrence differ between cancer types? A study from the population-based PROFILES registry. Psychooncology. 2015.
  5. Moran BJ, Holm T, Brannagan G, Chave H, Quirke P, West N, et al. The English national low rectal cancer development programme: key messages and future perspectives. Colorectal Dis. 2014;16(3):173-8. doi: 10.1111/codi.12501.
  6. Munkedal DL, West NP, Iversen LH, Hagemann-Madsen R, Quirke P, Laurberg S. Implementation of complete mesocolic excision at a university hospital in Denmark: An audit of consecutive, prospectively collected colon cancer specimens. Eur J Surg Oncol. 2014;40(11):1494-501. doi: 10.016/j.ejso.2014.04.004. Epub Jun 5.
  7. Quirke P, Palmer T, Hutchins GG, West NP. Histopathological work-up of resection specimens, local excisions and biopsies in colorectal cancer. Dig Dis. 2012;30(Suppl 2):2-8. doi: 10.1159/000341875. Epub 2012 Nov 23.
  8. Bertelsen CA, Neuenschwander AU, Jansen JE, Kirkegaard-Klitbo A, Tenma JR, Wilhelmsen M, et al. Short-term outcomes after complete mesocolic excision compared with 'conventional' colonic cancer surgery. The British journal of surgery. 2016:10083.
  9. Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CB, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696-701. doi: 10.1093/annonc/mdu560. Epub 2014 Dec 5.
  10. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50(11):1783-99.
  11. Nielsen M, Rasmussen P, Pedersen B, Hagemann-Madsen R, Lindegaard J, Laurberg S. Early and Late Outcomes of Surgery for Locally Recurrent Rectal Cancer: A Prospective 10-Year Study in the Total Mesorectal Excision Era. Annals of surgical oncology. 2015:7.
  12. Iversen LH, Rasmussen PC, Hagemann-Madsen R, Laurberg S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. Colorectal Dis. 2013;15(7):e365-72. doi: 10.1111/codi.12185.
  13. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013;100(8):E1-33.
  14. Poston GJ, Tait D, O'Connell S, Bennett A, Berendse S. Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ. 2011;343:d6751.(doi):10.1136/bmj.d6751.
  15. Benson AB, 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, et al. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015;13(6):719-28; quiz 28.
  16. Kusters M, Marijnen CA, van de Velde CJ, Rutten HJ, Lahaye MJ, Kim JH, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36(5):470-6. doi: 10.1016/j.ejso.2009.11.011. Epub 10 Jan 21.
  17. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998;114(1):7-14.
  18. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31(35):4465-70. doi: 10.1200/JCO.2013.50.7442. Epub 2013 Nov 12.
  19. Agarwal A, Marcus C, Xiao J, Nene P, Kachnic LA, Subramaniam RM. FDG PET/CT in the management of colorectal and anal cancers. AJR Am J Roentgenol. 2014;203(5):1109-19. doi: 10.2214/AJR.13.12256.
  20. Wille-Jorgensen P. Colofol. ESCP; 23. September 2015; Dublin2015.
  21. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311(3):263-70. doi: 10.1001/jama.2013.285718.
  22. Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;12:CD011134.(doi):10.1002/14651858.CD011134.pub2.
  23. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650-61. doi: 10.1158/2159-8290.CD-13-1014. Epub 2014 May 6.
  24. Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2015:2014-308859.
  25. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-6. doi: 10.038/nm.3967. Epub 2015 Oct 12.
  26. Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 2014;42(1):124-39. doi: 10.1177/0192623313505155. Epub 2013 Oct 31.
  27. Andreyev HJ. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol). 2007;19(10):790-9. Epub 2007 Sep 27.
  28. Lange MM, van de Velde CJ. Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol. 2011;8(1):51-7. doi: 10.1038/nrurol.2010.206. Epub Dec 7.
  29. Ho VP, Lee Y, Stein SL, Temple LK. Sexual function after treatment for rectal cancer: a review. Dis Colon Rectum. 2011;54(1):113-25. doi: 10.1007/DCR.0b013e3181fb7b82.
  30. Emmertsen KJ, Laurberg S. Identifying and Treating Patients With Pelvic Organ Dysfunction After Treatment for Pelvic Cancer. Dis Colon Rectum. 2016;59(1):83-5.
  31. Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer. 2001;92(4):896-902.
  32. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693-701.
  33. Chen TY, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer. 2015;14(2):106-14. doi: 10.1016/j.clcc.2014.12.007. Epub Dec 31.
  34. Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. AnnSurg. 2012;255(5):922-8.
  35. Machado M, Nygren J, Goldman S, Ljungqvist O. Functional and physiologic assessment of the colonic reservoir or side-to-end anastomosis after low anterior resection for rectal cancer: a two-year follow-up. Dis Colon Rectum. 2005;48(1):29-36.
  36. Emmertsen KJ, Laurberg S. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. BrJSurg. 2013;100(10):1377-87.
  37. Juul T, Ahlberg M, Biondo S, Emmertsen KJ, Espin E, Jimenez LM, et al. International Validation of the Low Anterior Resection Syndrome Score. AnnSurg. 2013.
  38. Bondeven P, Emmertsen KJ, Laurberg S, Pedersen BG. Neoadjuvant therapy abolishes the functional benefits of a larger rectal remnant, as measured by magnetic resonance imaging after restorative rectal cancer surgery. Eur J Surg Oncol. 2015;41(11):1493-9. doi: 10.016/j.ejso.2015.07.003. Epub Jul 15.
  39. Juul T, Ahlberg M, Biondo S, Espin E, Jimenez LM, Matzel KE, et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum. 2014;57(5):585-91. doi: 10.1097/DCR.0000000000000116.
  40. Bregendahl S, Emmertsen KJ, Fassov J, Krogh K, Zhao J, Gregersen H, et al. Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. RadiotherOncol. 2013.
  41. Floodeen H, Lindgren R, Hallbook O, Matthiessen P. Evaluation of long-term anorectal function after low anterior resection: a 5-year follow-up of a randomized multicenter trial. Dis Colon Rectum. 2014;57(10):1162-8. doi: 10.097/DCR.0000000000000197.
  42. Emmertsen KJ, Bregendahl S, Fassov J, Krogh K, Laurberg S. A hyperactive postprandial response in the neorectum - The clue to Low Anterior Resection Syndrome after TME surgery? Colorectal Dis. 2013.
  43. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 2007;8(11):1007-17.
  44. Andreyev HJ. Pelvic radiation disease. Colorectal Dis. 2015;17(1):2-6. doi: 10.1111/codi.12812.
  45. Andreyev HJ, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, et al. Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet. 2013;382(9910):2084-92. doi: 10.1016/S0140-6736(13)61648-7. Epub 2013 Sep 23.
  46. Battersby NJ, Juul T, Christensen P, Janjua AZ, Branagan G, Emmertsen KJ, et al. Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer: A Multicenter Cross-Sectional Study. Diseases of the colon and rectum. 2016;59(4):270-80.
  47. Martellucci J. Low Anterior Resection Syndrome: A Treatment Algorithm. Dis Colon Rectum. 2016;59(1):79-82.
  48. Pucciani F, Ringressi MN, Redditi S, Masi A, Giani I. Rehabilitation of fecal incontinence after sphincter-saving surgery for rectal cancer: encouraging results. Dis Colon Rectum. 2008;51(10):1552-8. doi: 10.007/s10350-008-9312-6. Epub 2008 May 2.
  49. Allgayer H, Dietrich CF, Rohde W, Koch GF, Tuschhoff T. Prospective comparison of short- and long-term effects of pelvic floor exercise/biofeedback training in patients with fecal incontinence after surgery plus irradiation versus surgery alone for colorectal cancer: clinical, functional and endoscopic/endosonographic findings. Scand J Gastroenterol. 2005;40(10):1168-75.
  50. Lin YH, Yang HY, Hung SL, Chen HP, Liu KW, Chen TB, et al. Effects of pelvic floor muscle exercise on faecal incontinence in rectal cancer patients after stoma closure. Eur J Cancer Care. 2015:12292.
  51. Rosen H, Robert-Yap J, Tentschert G, Lechner M, Roche B. Transanal irrigation improves quality of life in patients with low anterior resection syndrome. Colorectal Dis. 2011;13(10):e335-8. doi: 10.1111/j.463-318.2011.02692.x.
  52. Ramage L, Qiu S, Kontovounisios C, Tekkis P, Rasheed S, Tan E. A systematic review of sacral nerve stimulation for low anterior resection syndrome. Colorectal Dis. 2015;17(9):762-71. doi: 10.1111/codi.12968.
  53. Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61(2):179-92. doi: 10.1136/gutjnl-2011-300563. Epub 2011 Nov 4.
  54. Bregendahl S, Emmertsen KJ, Lindegaard JC, Laurberg S. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis. 2015;17(1):26-37. doi: 10.1111/codi.12758.
  55. Lange MM, Marijnen CA, Maas CP, Putter H, Rutten HJ, Stiggelbout AM, et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer. 2009;45(9):1578-88. doi: 10.016/j.ejca.2008.12.014. Epub 9 Jan 13.
  56. Hendren SK, O'Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005;242(2):212-23.
  57. Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control. 2010;17(1):44-51.
  58. Breukink SO, Donovan KA. Physical and psychological effects of treatment on sexual functioning in colorectal cancer survivors. J Sex Med. 2013;10(Suppl 1):74-83. doi: 10.1111/jsm.12037.
  59. Buchli C, Tapper J, Bottai M, Holm T, Arver S, Blomqvist L, et al. Testosterone and body composition in men after treatment for rectal cancer. J Sex Med. 2015;12(3):774-82. doi: 10.1111/jsm.12751. Epub 2014 Nov 12.